Advances in PET analyses of stress and dopamine
A deregulation of the stress response is a potential etiological factor in the development and relapse of dopamine (DA)-related human disorders, including addiction, drug-induced psychosis, and schizophrenia. Schizophrenia is characterized by a chronic relapsing nature and vulnerability to exacerbation following stress or dopaminergic drugs. Indeed, the most replicated finding so far in schizophrenia positron emission tomography (PET) research has been an increased DA release after the administration of amphetamine, and this DA increase has been associated with positive psychotic symptoms and active stages of the illness. As increased stimulantinduced DA release is a hallmark of sensitization, several pieces of evidence support the view that schizophrenia is associated with a process of dopamine sensitization (Laruelle and Abi-Dargham, 1999) .
Psychosis sufferers themselves often cite a link between the experience of stress and psychotic symptoms. The stress-vulnerability model suggests that an endogenous, organic diathesis or vulnerability interacts with internal or external stressors in the development of psychotic disorders. However, the underlying neurobiological condition/event that results in an exaggerated response to stressors is unknown. One proposed mechanism is neurochemical sensitization of the DA systemFdopamine sensitizationF, whereby repeated exposure to sensitizing life stressors (or DA drugs) progresses into increased stress-associated DA release. Hence, during active periods of the illness (that is, prodromal phase, initial episode, and subsequent relapses), dopaminergic neurons may be hyperresponsive to environmental stimuli, and exposure to even moderate levels of stress (or DA drugs) produces excessive DA release, precipitating illness in vulnerable individuals and relapse in those with schizophrenia.
The phenomenon of DA sensitization to psychostimulants is subjected to cross-sensitization with stress. It is well established that repeated stress (maternal separation, social-defeat stress, foot shock, tail pinch, restraint) induces heightened sensitivity to low doses of dopaminergic drugs; and conversely, repeated dopaminergic drug exposure increases the stress response in animals. Consistent with these findings, prenatal and postnatal stress is associated with increased drug-induced DA release, and different types of acute and repeated stress increase DA release (Abercrombie et al, 1989; Kalivas et al, 1986) . Similarly, recent studies in humans using PET have shown increased DA release after either a psychosocial or a metabolic stress task (Adler et al, 2000; Pruessner et al, 2004) . However, this finding was not replicated in another study, which used a different stress paradigm, with no The next logical step is to test whether stress produces a deregulated DA response in clinical populations, such as those with psychotic disorders, addictions, as well as in those at risk. We tested both drug-free patients with schizophrenia and clinical high risk (CHR) for psychosis (that is, putatively prodromal) diagnosed with the Criteria of Prodromal Syndromes in a two-scan protocol: one while doing a Sensory Motor Control Task and another one while doing the Montreal Imaging Stress Task. Our pilot data suggests an increased stressinduced DA release as compared with matched healthy volunteers (HVs) (Figure 1 ). This kind of studies has important theoretical and clinical implications regarding the prevention of relapse and efforts to abort or delay conversion to psychosis. . Vascular brain changes on imaging studies have long been associated with LLD. Genetic analysis of vascular changes is an emerging field, and recent work in older populations has focused on polymorphisms associated with (1) psychiatric disease in younger adults or (2) vascular risk factors. We have previously reported links between BDNF (brain-derived neurotrophic factor) polymorphisms (Taylor et al, 2008) and serotonin transporter-linked polymorphic region (5HTTLPR) polymorphisms (Steffens et al, 2008) and white matter hyperintensity (WMH) volumes, supporting theories that these genes also have a role in LLD. The notion that WMHs are vascular in nature led our group to explore relationships between WMH volume and genes associated with systemic vascular risk. These include renin-angiotensin system genes, such as the angiotensin II receptor, vascular types 1 and 2 (AGTR1 and AGTR2) genes. In addition to reports linking AGTR1 polymorphisms to LLD outcomes, we have also found genderspecific associations between AGTR polymorphisms and WMH progression (Taylor et al, 2009) . Similarly, the methylenetetrahydrofolate reductase (MTHFR) gene, another vascular risk gene associated with folate and homocysteine metabolism, may be associated with LLD, and we are examining MTHFR and other genes related to folate metabolism in the occurrence of white matter lesions in LLD. Our studies continue to examine the role of vascular risk genes in LLD, focusing on their influence on brain structure and cognition.
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Consistent with the vascular depression hypothesis is the notion the LLD is associated with disruption in frontalstriatal circuitry. These abnormalities in the prefrontal cortex, striatum, and frontal-striatal white matter tracks are also likely related to genetic differences. A previous study noted a link between the 5HTTLPR short allele and caudate volume in LLD. We recently reported an interaction between two genes, COMT (catechol-O-methyltransferase) and MTHFR, and putamen volume reduction in LLD (Pan et al, 2009) . Identification of genes associated with prefrontal cortical structure and function remains an active area of inquiry.
Beyond the vascular depression hypothesis, another avenue of genetic/neuroimaging LLD research examines the observed link between depression and later dementia. The hippocampus is a key structure related to both LLD pathophysiology and increased dementia risk. The APOE gene is associated with both depression and Alzheimer's disease, and APOE genotype has been associated with specific shape differences in geriatric depression (Qiu et al, 2009 ). Allelic differences in the 5HTTLPR gene have also been associated with hippocampal volume in LLD by several groups.
Advances in both neuroimaging technologies and genetic assessment allow us to investigate the pathophysiology of affective disorders. Existing paradigms of vascular depression and depression as dementia risk make LLD ideally suited for future genetic/imaging studies.
